Search Result

Results for "

C. difficile

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (10) ATP Synthase (1) Autophagy (1) Bacterial (20) DNA/RNA Synthesis (3) Isotope-Labeled Compounds (2) MDM-2/p53 (1)
By Research Areas:	Cancer (1) Infection (22) Inflammation/Immunology (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9929

Bezlotoxumab	Bacterial	Infection Inflammation/Immunology
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .

HY-B0975

Penicillin V Potassium Phenoxymethylpenicillin potassium salt	Bacterial Antibiotic	Infection
Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-18324

CRS3123 REP-3123	Antibiotic	Inflammation/Immunology
CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNA synthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections .

HY-128357

Ibezapolstat 1 Publications Verification ACX-362E; GLS-362E	Bacterial DNA/RNA Synthesis	Infection
Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a K_i of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI) .

HY-156283

Antibacterial agent 159	Antibiotic	Infection
Antibacterial agent 159 (Compound 6d) is an antibiotic. Antibacterial agent 159 can effective against impetigo and C. difficile infection (CDI). Antibacterial agent 159 has no observed recurrence for C. difficile and exertes a minimal impact on the beneficial gut microbiome .

HY-156191

Cholic acid anilide	Bacterial	Infection
Cholic acid anilide, a Narylcholan-24-amide, is a potent inhibitor of C. difficile spore germination with an IC₅₀ value of 1.8 μM in the spore germination assay conducted in Sodium phosphate media containing 6 mM Taurocholate (HY-B1131) and 12 mM Glycine (HY-Y0966). Cholic acid anilide has the potential for C. difficile infections research .

HY-B0975R

Penicillin V Potassium (Standard)	Bacterial Antibiotic	Infection
Penicillin V (Potassium) (Standard) is the analytical standard of Penicillin V (Potassium). This product is intended for research and analytical applications. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-128357A

Ibezapolstat hydrochloride ACX-362E hydrochloride; GLS-362E hydrochloride	Bacterial DNA/RNA Synthesis	Infection
Ibezapolstat hydrochloride is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a K_i of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat hydrochloride is developed for the research of C. difficile infection(CDI) .

HY-163142

Antibacterial agent 172	Bacterial	Infection
Antibacterial agent 172 (Compound 6a) is a <,i>Clostridioides difficile (Cd) SpoVD inhibitor (IC₅₀=89 nM) that effectively inhibits sporulation of Clostridioides difficile. Antibacterial agent 172 can be used in the study of bacterial infections .

HY-156282

Antibacterial agent 158	Bacterial	Infection
Antibacterial agent 158 (compound 6c), a Micrococcin analogue, and is effective against impetigo and C. difficile* infection* (CDI) .

HY-16753

Ridinilazole SMT19969	Bacterial	Infection
Ridinilazole is a novel antibacterial with MICs range of 0.06-0.25 µg/mL (MIC₉₀=8 µg/mL) against C. difficile.

HY-123354

SC 44914	Bacterial	Infection
SC 44914 is a quinoxaline compound with antibacterial effects. SC-44914 has activity against Campylobacter jejuni, C. coli, and Clostridium difficile .

HY-W749146

Raja 42	Antibiotic Bacterial	Infection
Raja 42 is a gamma lactam antibiotic. Raja 42 is effective against a variety of different bacterias, including Gram-positive and Gram-negative bacteria, such as C. difficile strains .

HY-171005

VPC162134	Bacterial	Infection
VPC162134 is an antibacterial agent, that inhibits H. pylori, C. jejuni, MRSA and S. epidermidis with MIC of 2.9, 17.5, 93.3 and 93.3 μM. VPC162134 is an inhibitor for pyruvate ferredoxin oxidoreductase (PFOR) .

HY-B0975S

Penicillin V-13C6 potassium Phenoxymethylpenicillin-¹³C₆ potassium salt	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Penicillin V- ¹³C₆ (potassium) is the ¹³C₆ labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.

HY-163042

HSGN-218	Bacterial	Infection
HSGN-218 is an antibacterial agent with low Caco-2 permeability. HSGN-218 efficiently inhibits the growth of different C. difficile species with MIC values ranging from 0.007 μM to 0.07 μM.

HY-148041

ATPase-IN-2	ATP Synthase	Others
ATPase-IN-2 is an ATPase inhibitor with an IC₅₀ value of 0.9 μM. ATPase-IN-2 inhibits C. difficile toxin B (TcdB) glycohydrolase activity with an AC₅₀ value of 30.91 μM. ATPase-IN-2 can be used for the research of ATP-related .

HY-149610

Antibacterial agent 156	Bacterial	Infection
Antibacterial agent 156 (Compound 57) is a selective and potent bactericidal against C. difficile and targets cell-wall synthesis. Antibacterial agent 156 exhibits bactericidal activity with the minimal inhibitory concentration of 0.5 μg/mL and 1 μg/mL against MIMIC50 (101 strains) and MIC90 (101 strains) .

HY-B0975AR

Penicillin V (Standard)	Antibiotic Bacterial	Infection
Penicillin V (Standard) is the analytical standard of Penicillin V. This product is intended for research and analytical applications. Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis [4].

HY-B0975A

Penicillin V Phenoxymethylpenicillin	Antibiotic Bacterial	Infection
Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-B0975S1

Penicillin V-d5 potassium Phenoxymethylpenicillin-d₅ potassium salt	Bacterial Antibiotic	Infection
Penicillin V-d₅ (potassium) is the deuterium labeled Penicillin V Potassium[1]. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis[2][3][4][5].

HY-B0975AS

Penicillin V-d5	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Penicillin V-d₅ (Phenoxymethylpenicillin-d5) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis[1][2][3][4].

HY-105099

Rifalazil KRM-1648; ABI-1648	DNA/RNA Synthesis Bacterial	Infection Inflammation/Immunology
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

Cat. No.	Product Name	Target	Research Area

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

Cat. No.	Product Name	Target	Research Area

HY-P99277

Actoxumab Anti-C. difficile Toxin A Recombinant Antibody	Inhibitory Antibodies	Infection
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .

HY-P9929

Bezlotoxumab	Bacterial	Infection Inflammation/Immunology
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .

Penicillin V Potassium Phenoxymethylpenicillin potassium salt	Infection Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Disease Research Fields Beta-lactam Antibiotics	Bacterial Antibiotic
Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

Penicillin V Potassium (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Antibiotics Source classification Antibacterial Disease Research Beta-lactam Antibiotics	Bacterial Antibiotic
Penicillin V (Potassium) (Standard) is the analytical standard of Penicillin V (Potassium). This product is intended for research and analytical applications. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

Cat. No.	Compare	Product Name	Species	Source

HY-P79219

	*Toxin B/TcdB Protein, C. difficile* (His)** Toxin B; Glucosyltransferase TcdB; toxB	Others	E. coli
	Toxin B/TcdB protein is the precursor of the cytotoxin TcdB, which can strategically destroy the colon epithelium and cause host inflammatory response and diarrhea in Clostridium difficile infection. Compared with TcdA, TcdB has higher virulence and is essential for eliciting host responses. Toxin B/TcdB Protein, C. difficile (His) is the recombinant Toxin B/TcdB protein, expressed by E. coli , with C-6*His labeled tag. The total length of Toxin B/TcdB Protein, C. difficile (His) is 543 a.a., with molecular weight of approximately 65 kDa.

Compare Products

Products

Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample
Size

Cat. No.	Product Name	Chemical Structure

HY-B0975S

Penicillin V-13C6 potassium
Penicillin V- ¹³C₆ (potassium) is the ¹³C₆ labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.

HY-B0975S1

Penicillin V-d5 potassium
Penicillin V-d₅ (potassium) is the deuterium labeled Penicillin V Potassium[1]. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis[2][3][4][5].

HY-B0975AS

Penicillin V-d5
Penicillin V-d₅ (Phenoxymethylpenicillin-d5) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis[1][2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

C. difficile

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products